| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2766 | 2016 |
| Revised international staging system for multiple myeloma: a report from International Myeloma Working Group A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ... Journal of clinical oncology 33 (26), 2863-2869, 2015 | 2343 | 2015 |
| Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021 | 1809 | 2021 |
| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1662 | 2016 |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1645 | 2015 |
| Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International … MA Gertz, R Comenzo, RH Falk, JP Fermand, BP Hazenberg, ... American journal of hematology 79 (4), 319-328, 2005 | 1591 | 2005 |
| Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1573 | 2015 |
| Lenalidomide maintenance after stem-cell transplantation for multiple myeloma M Attal, V Lauwers-Cances, G Marit, D Caillot, P Moreau, T Facon, ... New England Journal of Medicine 366 (19), 1782-1791, 2012 | 1441 | 2012 |
| Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma M Attal, V Lauwers-Cances, C Hulin, X Leleu, D Caillot, M Escoffre, ... New England Journal of Medicine 376 (14), 1311-1320, 2017 | 1322 | 2017 |
| Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1281 | 2016 |
| Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome H Avet-Loiseau, M Attal, P Moreau, C Charbonnel, F Garban, C Hulin, ... Blood 109 (8), 3489-3495, 2007 | 1246 | 2007 |
| Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study P Moreau, H Pylypenko, S Grosicki, I Karamanesht, X Leleu, ... The lancet oncology 12 (5), 431-440, 2011 | 1216 | 2011 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1048 | 2013 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ... The Lancet Oncology 17 (1), 27-38, 2016 | 1037 | 2016 |
| Heterogeneity of genomic evolution and mutational profiles in multiple myeloma N Bolli, H Avet-Loiseau, DC Wedge, P Van Loo, LB Alexandrov, ... Nature communications 5 (1), 2997, 2014 | 1011 | 2014 |
| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA … P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ... The Lancet 394 (10192), 29-38, 2019 | 996 | 2019 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 996 | 2016 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 985 | 2012 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 949 | 2019 |
| Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, ... New England Journal of Medicine 371 (10), 906-917, 2014 | 949 | 2014 |
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of Medicinemed.uoa.gr üzerinde doğrulanmış e-posta adresine sahip
